FDA-cleared mobile ECG iMedrix offers KardioScreen, a US FDA-cleared mobile-connected 12 and 6 lead ECG device, presenting a compelling entry point for hospitals, clinics, EMS, and home-health providers seeking portable, clinically validated cardiac monitoring solutions.

Global validation footprint Clinical trace capability across more than 450,000 ECGs in 15 countries indicates strong real-world efficacy and reliability, creating an opportunity to pursue international hospital networks, medical distributors, and telehealth partners seeking proven performance.

AI driven workflows A commitment to AI, cloud, and ML for quick diagnosis positions the product to integrate with digital health platforms, EHRs, and AI-enabled triage services, enabling upsell to value-based care and accelerated decision support.

Strategic partnerships Recent collaborations such as the MoyoAfya project with NCD Alliance Kenya and Philips Foundation demonstrate a path to public health programs and government-backed initiatives, suggesting sales routes through NGOs, health ministries, and humanitarian programs.

Growth-ready yet lean With 11-50 employees and revenue under one million, iMedrix presents a nimble, rapidly scalable partner for OEM collaborations, white-label opportunities, and pilot deployments in regional hospital networks or care-at-home programs to build volume before larger incumbents.